This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Asakuma, J. Articles by Hayakawa, M. Search for Related Content PubMed PubMed Citation Articles by Asakuma, J. Articles by Hayakawa, M.

Selective Akt Inactivation and Tumor Necrosis Factor-related Apoptosis-inducing Ligand Sensitization of Renal Cancer Cells by Low Concentrations of Paclitaxel

Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan

Recent studies demonstrated that the resistance of cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) could be reversed by various chemotherapeutic agents. In the present study, we investigated the role of Akt in the apoptosis resistance to TRAIL and chemotherapeutic agents-induced TRAIL sensitization in human renal cell carcinoma cells. Apoptosis assays and Western blot analyses revealed that apoptosis resistance to TRAIL correlates well with the level of Akt phosphorylation at Ser 473 rather than protein expression levels of TRAIL receptors, DR4 and DR5. The apoptosis sensitivity to TRAIL in TRAIL-resistant SKRC-49 and TRAIL-sensitive Caki-1 cells was altered by modulation of Akt activity, which increased the protein expression of cellular FADD-like IL-1ß-converting enzyme-like inhibitory protein (cFLIP). Paclitaxel (5 and 100 nM) and cisplatin (10 µM) but not etoposide (1 and 10 µM) promoted TRAIL-induced apoptosis in SKRC-49 cells, which was not mediated by increased TRAIL receptor expression but by chemotherapeutic agents-induced Akt inactivation through ceramide formation derived from sphingomyelin hydrolysis. Of note, the low concentration (5 nM) of paclitaxel promoted ceramide formation and TRAIL-induced apoptosis predominantly in SKRC-49 cells but not in the normal renal proximal tubular epithelial cells. Our results may provide a novel therapeutic modality for selective killing of renal cell carcinoma with minimal toxicity on normal renal cells.

This article has been cited by other articles:

				S. Macher-Goeppinger, S. Aulmann, K. E. Tagscherer, N. Wagener, A. Haferkamp, R. Penzel, A. Brauckhoff, M. Hohenfellner, J. Sykora, H. Walczak, et al. Prognostic Value of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer Clin. Cancer Res., January 15, 2009; 15(2): 650 - 659. [Abstract] [Full Text] [PDF]

				H. Hu, C. Jiang, T. Schuster, G.-X. Li, P. T. Daniel, and J. Lu Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway. Mol. Cancer Ther., July 1, 2006; 5(7): 1873 - 1882. [Abstract] [Full Text] [PDF]

				J. Huh, A. Liepins, J. Zielonka, C. Andrekopoulos, B. Kalyanaraman, and A. Sorokin Cyclooxygenase 2 Rescues LNCaP Prostate Cancer Cells from Sanguinarine-Induced Apoptosis by a Mechanism Involving Inhibition of Nitric Oxide Synthase Activity. Cancer Res., April 1, 2006; 66(7): 3726 - 3736. [Abstract] [Full Text] [PDF]

				D. Pchejetski, M. Golzio, E. Bonhoure, C. Calvet, N. Doumerc, V. Garcia, C. Mazerolles, P. Rischmann, J. Teissie, B. Malavaud, et al. Sphingosine Kinase-1 as a Chemotherapy Sensor in Prostate Adenocarcinoma Cell and Mouse Models Cancer Res., December 15, 2005; 65(24): 11667 - 11675. [Abstract] [Full Text] [PDF]

				K. Zhu, E. Gerbino, D. M. Beaupre, P. A. Mackley, C. Muro-Cacho, C. Beam, A. D. Hamilton, M. G. Lichtenheld, W. G. Kerr, W. Dalton, et al. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells Blood, June 15, 2005; 105(12): 4759 - 4766. [Abstract] [Full Text] [PDF]

				X. Zhang, T.-G. Jin, H. Yang, W. C. DeWolf, R. Khosravi-Far, and A. F. Olumi Persistent c-FLIP(L) Expression Is Necessary and Sufficient to Maintain Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer Cancer Res., October 1, 2004; 64(19): 7086 - 7091. [Abstract] [Full Text] [PDF]

				M. Sumitomo, T. Asano, J. Asakuma, T. Asano, A. Horiguchi, and M. Hayakawa ZD1839 Modulates Paclitaxel Response in Renal Cancer by Blocking Paclitaxel-Induced Activation of the Epidermal Growth Factor Receptor-Extracellular Signal-Regulated Kinase Pathway Clin. Cancer Res., January 15, 2004; 10(2): 794 - 801. [Abstract] [Full Text] [PDF]

				L. E. Broker, C. Huisman, S. W. Span, J. A. Rodriguez, F. A. E. Kruyt, and G. Giaccone Cathepsin B Mediates Caspase-Independent Cell Death Induced by Microtubule Stabilizing Agents in Non-Small Cell Lung Cancer Cells Cancer Res., January 1, 2004; 64(1): 27 - 30. [Abstract] [Full Text] [PDF]

				S. Grether-Beck, I. Felsner, H. Brenden, and J. Krutmann Mitochondrial Cytochrome c Release Mediates Ceramide-induced Activator Protein 2 Activation and Gene Expression in Keratinocytes J. Biol. Chem., November 28, 2003; 278(48): 47498 - 47507. [Abstract] [Full Text] [PDF]